Recombinant human gh

Data reported here are from the baseline (pre-treatment) and 6-week visits of a subset of 15 consecutive participants (mean age: 34±6 years; mean BMI: 37.7±6.1 kg/m, mean IGF-1 standard deviations core (SDS): −1.9±0.5) in a double-blind, randomized, placebo-controlled trial of GH vs placebo [4 (link)]. Subjects were randomized to daily subcutaneous recombinant human GH (Genentech, Inc) (starting dose 2 μg/kg/d) (n= 6) or placebo (n=9). Participants in the placebo group were sham dose-adjusted to maintain blinding to randomization assignment. A glucagon GH stimulation test was performed pre-treatment, and IGF-1 levels were measured at baseline, 3 and 6 weeks; GH doses were adjusted based on IGF-1 levels as previously described [4 (link)]. Serum fasting glucose and insulin were measured and an oral glucose tolerance test was performed at baseline and 6 weeks.

Murine 3T3-F442A preadipocytes were provided by H. Green (Harvard University) and M. Sonenberg (Sloan-Kettering, NY). The 293T human kidney cell line was provided by M. Lazar (University of Pennsylvania) and O. MacDougald (University of Michigan). Recombinant human GH (lot # AFP8990A) for cell culture studies was purchased from the National Hormone and Pituitary Program (Torrance, CA). Recombinant human GH (Lot# N70315) for animal experiments was from Genentech (San Francisco, CA), courtesy of Dr. R.K. Menon (University of Michigan). Insulin, dexamethasone, isobutylmethylxanthine, formaldehyde, Bradford reagent, sodium orthovanadate and SYBR green were from Sigma (St. Louis, MO). Culture media, L-glutamine, and antibiotic-antimycotic were purchased from Invitrogen (Grand Island, NY). Fetal bovine serum (FBS) and calf serum (CS) were from Atlanta Biologicals (Lawrenceville, GA). Bovine serum albumin (BSA, fatty acid-free, cat. # 62150101) was purchased from Proliant (Ankeny, IA). Protease inhibitors leupeptin and aprotinin were purchased from Roche (Indianapolis, IN), and phenylmethylsulfonylfluoride (PMSF) from Mallinckrodt (St. Louis, MO).